⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068640 | 0.58 | — | — | |
| SCHEMBL6064185 | 0.56 | — | — | |
| SCHEMBL1008893 | 0.55 | — | — | |
| SCHEMBL17653012 | 0.55 | — | — | |
| SCHEMBL6167167 | 0.55 | — | — | |
| SCHEMBL14413181 | 0.53 | — | — | |
| SCHEMBL12937701 | 0.53 | — | — | |
| SCHEMBL2044223 | 0.53 | — | — | |
| SCHEMBL7139212 | 0.53 | — | — | |
| SCHEMBL1743394 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050312-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | THE BROAD INSTITUTE, INC. (US) | 2024-03-07 | — | — | WO | claimed |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | claimed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | claimed |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | claimed |
| WO-2024050312-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | THE BROAD INSTITUTE, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | disclosed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |